These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 12646035)

  • 21. Trends in active pharmaceutical ingredient salt selection based on analysis of the Orange Book database.
    Paulekuhn GS; Dressman JB; Saal C
    J Med Chem; 2007 Dec; 50(26):6665-72. PubMed ID: 18052022
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rationalizing the selection of oral lipid based drug delivery systems by an in vitro dynamic lipolysis model for improved oral bioavailability of poorly water soluble drugs.
    Dahan A; Hoffman A
    J Control Release; 2008 Jul; 129(1):1-10. PubMed ID: 18499294
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Physicochemical property profiles of marketed drugs, clinical candidates and bioactive compounds.
    Tyrchan C; Blomberg N; Engkvist O; Kogej T; Muresan S
    Bioorg Med Chem Lett; 2009 Dec; 19(24):6943-7. PubMed ID: 19879759
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Automated selection of compounds with physicochemical properties to maximize bioavailability and druglikeness.
    Oashi T; Ringer AL; Raman EP; Mackerell AD
    J Chem Inf Model; 2011 Jan; 51(1):148-58. PubMed ID: 21142079
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Matched molecular pairs as a guide in the optimization of pharmaceutical properties; a study of aqueous solubility, plasma protein binding and oral exposure.
    Leach AG; Jones HD; Cosgrove DA; Kenny PW; Ruston L; MacFaul P; Wood JM; Colclough N; Law B
    J Med Chem; 2006 Nov; 49(23):6672-82. PubMed ID: 17154498
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States.
    Stepan AF; Walker DP; Bauman J; Price DA; Baillie TA; Kalgutkar AS; Aleo MD
    Chem Res Toxicol; 2011 Sep; 24(9):1345-410. PubMed ID: 21702456
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oral formulation strategies to improve solubility of poorly water-soluble drugs.
    Singh A; Worku ZA; Van den Mooter G
    Expert Opin Drug Deliv; 2011 Oct; 8(10):1361-78. PubMed ID: 21810062
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The influence of target family and functional activity on the physicochemical properties of pre-clinical compounds.
    Morphy R
    J Med Chem; 2006 May; 49(10):2969-78. PubMed ID: 16686538
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
    Alelyunas YW; Empfield JR; McCarthy D; Spreen RC; Bui K; Pelosi-Kilby L; Shen C
    Bioorg Med Chem Lett; 2010 Dec; 20(24):7312-6. PubMed ID: 21055935
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A biopharmaceutical classification-based Right-First-Time formulation approach to reduce human pharmacokinetic variability and project cycle time from First-In-Human to clinical Proof-Of-Concept.
    Ku MS; Dulin W
    Pharm Dev Technol; 2012; 17(3):285-302. PubMed ID: 21121705
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Property distribution of drug-related chemical databases.
    Oprea TI
    J Comput Aided Mol Des; 2000 Mar; 14(3):251-64. PubMed ID: 10756480
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PBPK models for the prediction of in vivo performance of oral dosage forms.
    Kostewicz ES; Aarons L; Bergstrand M; Bolger MB; Galetin A; Hatley O; Jamei M; Lloyd R; Pepin X; Rostami-Hodjegan A; Sjögren E; Tannergren C; Turner DB; Wagner C; Weitschies W; Dressman J
    Eur J Pharm Sci; 2014 Jun; 57():300-21. PubMed ID: 24060672
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of specific "drug-like property" rules for carboxylate-containing oral drug candidates.
    Böcker A; Bonneau PR; Hucke O; Jakalian A; Edwards PJ
    ChemMedChem; 2010 Dec; 5(12):2102-13. PubMed ID: 20979082
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetic comparisons of tail-bleeding with cannula- or retro-orbital bleeding techniques in rats using six marketed drugs.
    Hui YH; Huang NH; Ebbert L; Bina H; Chiang A; Maples C; Pritt M; Kern T; Patel N
    J Pharmacol Toxicol Methods; 2007; 56(2):256-64. PubMed ID: 17618130
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Physical chemical considerations of lipid-based oral drug delivery--solid lipid nanoparticles.
    Bummer PM
    Crit Rev Ther Drug Carrier Syst; 2004; 21(1):1-20. PubMed ID: 15099183
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Drugs in other drugs: a new look at drugs as fragments.
    Siegel MG; Vieth M
    Drug Discov Today; 2007 Jan; 12(1-2):71-9. PubMed ID: 17198975
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A win-win solution in oral delivery of lipophilic drugs: supersaturation via amorphous solid dispersions increases apparent solubility without sacrifice of intestinal membrane permeability.
    Miller JM; Beig A; Carr RA; Spence JK; Dahan A
    Mol Pharm; 2012 Jul; 9(7):2009-16. PubMed ID: 22632106
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diverse approaches for the enhancement of oral drug bioavailability.
    Fasinu P; Pillay V; Ndesendo VM; du Toit LC; Choonara YE
    Biopharm Drug Dispos; 2011 May; 32(4):185-209. PubMed ID: 21480294
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim.
    Sjögren E; Westergren J; Grant I; Hanisch G; Lindfors L; Lennernäs H; Abrahamsson B; Tannergren C
    Eur J Pharm Sci; 2013 Jul; 49(4):679-98. PubMed ID: 23727464
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characteristics of polymers enabling nano-comminution of water-insoluble drugs.
    Lee J; Choi JY; Park CH
    Int J Pharm; 2008 May; 355(1-2):328-36. PubMed ID: 18261866
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.